Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products

PHASE3RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 9, 2025

Primary Completion Date

June 26, 2026

Study Completion Date

June 26, 2026

Conditions
Congenital Hemophilia A
Interventions
BIOLOGICAL

Recombinant single-chain factor VIII (rVIII-SingleChain)

Lyophilized powder for solution for intravenous injection

Trial Locations (16)

63000

NOT_YET_RECRUITING

North China University of Science and Technology Affiliated Hospital, Tangshan

81000

RECRUITING

Quinghai Provincial People's Hospital, Xining

100045

RECRUITING

Beijing Children's Hospital, Beijing

200020

NOT_YET_RECRUITING

Shanghai Jiaotong University School of Medicine, Ruijin Hospital, Shanghai

NOT_YET_RECRUITING

The Children's Hospital Zhejiang University School of Medicine, Shanghai

212028

RECRUITING

Jiangxi Provincial People's Hospital, Nanchang

221006

RECRUITING

XuZhou Children's Hospital, Xuzhou

230000

NOT_YET_RECRUITING

The Second Hospital of Anhui Medical University, Hefei

266071

RECRUITING

Qingdao Women and Children's Hospital, Qingdao

300020

RECRUITING

Hospital of Hematology, Chinese Academy of Medical Sciences, Tianjin

350001

RECRUITING

Fujian Medical University Union Hospital, Fuzhou

410021

RECRUITING

Hunan Provincial Children's Hospital, Changsha

510623

RECRUITING

Guangzhou Women and Children's Medical Center, Guangzhou

515399

RECRUITING

Nanfang Hospital of Southern Medical University, Guangzhou

545006

RECRUITING

Liuzhou People's Hospital, Liuzhou

650011

RECRUITING

The second affiliated hospital of Kunming Medical University, Kunming

Sponsors

Lead Sponsor

All Listed Sponsors
lead

CSL Behring

INDUSTRY

NCT06738485 - Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products | Biotech Hunter | Biotech Hunter